Publications by authors named "Paul Sabbatini"

95Publications

Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.

Gynecol Oncol 2020 Nov 16;159(2):418-425. Epub 2020 Aug 16.

The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.07.104DOI Listing
November 2020

Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.

Gynecol Oncol 2020 Aug 2;158(2):303-308. Epub 2020 Jun 2.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weil Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.04.710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423717PMC
August 2020

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.

Gynecol Oncol 2020 04 17;157(1):214-221. Epub 2020 Jan 17.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, United States of America; Department of Medicine, Weill Cornell Medical College, 1300 York Ave., New York, NY 10021, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127949PMC
April 2020

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

N Engl J Med 2019 11;381(20):1929-1939

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941470PMC
November 2019

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Gynecol Oncol 2019 02 22;152(2):251-258. Epub 2018 Nov 22.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613945PMC
February 2019

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 08;23(8):1004

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0817-1004cDOI Listing
August 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Int J Gynecol Cancer 2016 Feb;26(2):255-60

Departments of *Medicine and †Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; ‡Sanofi Statistics Department, Cambridge MA; and §Department of Radiology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009457PMC
February 2016

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

J Clin Oncol 2016 Feb 7;34(6):557-65. Epub 2015 Dec 7.

Ethan Basch, Mark G. Kris, Howard I. Scher, Clifford A. Hudis, Paul Sabbatini, Lauren Rogak, Thomas M. Atkinson, Joanne F. Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY; Ethan Basch, Allison M. Deal, and Antonia V. Bennett, University of North Carolina, Chapel Hill, NC; Amylou C. Dueck, Mayo Clinic, Scottsdale, AZ; Allison Barz, Children's Hospital of Philadelphia, Philadelphia, PA; Paul Novotny and Jeff A. Sloan, Mayo Clinic, Rochester, MN; and Deborah Schrag, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.0830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872028PMC
February 2016

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Drug Discov Today 2015 Dec 28;20(12):1422-8. Epub 2015 Aug 28.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2015.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940024PMC
December 2015

Ovarian cancer, version 2.2013.

J Natl Compr Canc Netw 2013 Oct;11(10):1199-209

From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0142DOI Listing
October 2013

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Cancer 2012 May 20;118(9):2403-10. Epub 2011 Sep 20.

Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245795PMC
May 2012

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Immunotherapy 2011 Feb;3(2):153-62

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.10.100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221001PMC
February 2011

Abagovomab for ovarian cancer.

Expert Opin Biol Ther 2011 Mar 18;11(3):395-403. Epub 2011 Jan 18.

Klinik für Gyäkologie und Geburtshilfe Städtisches Klinikum Solingen, Gotenstr. 1, 42653 Solingen, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14712598.2011.55
Publisher Site
http://dx.doi.org/10.1517/14712598.2011.553598DOI Listing
March 2011

Consolidation therapy in ovarian cancer: a clinical update.

Authors:
Paul Sabbatini

Int J Gynecol Cancer 2009 Dec;19 Suppl 2:S35-9

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181c14007DOI Listing
December 2009

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

Clin Cancer Res 2010 Jan 22;16(1):358-66. Epub 2009 Dec 22.

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211604PMC
January 2010

Epothilones: better or more of the same?

J Clin Oncol 2009 Jul 18;27(19):3079-81. Epub 2009 May 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.6481DOI Listing
July 2009

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

Gynecol Oncol 2009 Mar 9;112(3):563-7. Epub 2009 Jan 9.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.11.027DOI Listing
March 2009

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Gynecol Oncol 2008 Dec 30;111(3):455-60. Epub 2008 Sep 30.

Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.07.049DOI Listing
December 2008

Harnessing the immune system for ovarian cancer therapy.

Am J Reprod Immunol 2008 Jan;59(1):62-74

Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0897.2007.00560.xDOI Listing
January 2008

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Gynecol Oncol 2008 Feb 13;108(2):287-92. Epub 2007 Nov 13.

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave. New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2007.10.001DOI Listing
February 2008

Immunologic approaches to ovarian cancer treatment.

J Clin Oncol 2007 Jul;25(20):2884-93

Medical Gynecologic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.0775DOI Listing
July 2007

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.

Invest New Drugs 2007 Aug 16;25(4):335-41. Epub 2007 Mar 16.

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-007-9035-xDOI Listing
August 2007

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

J Clin Oncol 2007 Mar 29;25(9):1082-8. Epub 2007 Jan 29.

Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.08.7304DOI Listing
March 2007

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Gynecol Oncol 2007 Feb 4;104(2):435-42. Epub 2006 Oct 4.

Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2006.08.028DOI Listing
February 2007

Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary.

Gynecol Oncol 2006 Oct 13;103(1):31-4. Epub 2006 Mar 13.

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-1096, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2006.01.050DOI Listing
October 2006

New agents and new formulations for the treatment of ovarian cancer.

Authors:
Paul Sabbatini

Clin Adv Hematol Oncol 2005 Nov;3(11):840-2

Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, USA.

View Article

Download full-text PDF

Source
November 2005

Consolidation for ovarian cancer in remission.

J Clin Oncol 2006 Feb;24(4):537-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.5138DOI Listing
February 2006

Patient online self-reporting of toxicity symptoms during chemotherapy.

J Clin Oncol 2005 May;23(15):3552-61

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.275DOI Listing
May 2005

Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.

Gynecol Oncol 2005 Feb;96(2):330-4

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.09.058DOI Listing
February 2005

Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.

Gynecol Oncol 2004 Oct;95(1):235-41

Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.07.035DOI Listing
October 2004

Early detection and prognosis of ovarian cancer using serum YKL-40.

J Clin Oncol 2004 Aug;22(16):3330-9

Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.09.112DOI Listing
August 2004

Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.

Gynecol Oncol 2004 Apr;93(1):223-8

Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021,USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.01.014DOI Listing
April 2004

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

Gynecol Oncol 2003 Oct;91(1):123-9

Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-8258(03)00464-5DOI Listing
October 2003

Anemia clinical practice guidelines in oncology.

Authors:
Paul Sabbatini

J Natl Compr Canc Netw 2003 Jan;1 Suppl 1:S2-13

Memorial Sloan-Kettering Cancer Center, USA.

View Article

Download full-text PDF

Source
January 2003

Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report.

Gynecol Oncol 2002 Oct;87(1):138-42

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2002.6717DOI Listing
October 2002

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Clin Cancer Res 2002 Aug;8(8):2505-11

The Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
August 2002

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

J Clin Oncol 2002 Mar;20(5):1238-47

Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.5.1238DOI Listing
March 2002

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

Gynecol Oncol 2002 Mar;84(3):378-82

Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2001.6519DOI Listing
March 2002

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

J Clin Oncol 2002 Feb;20(3):694-8

Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2002.20.3.694
Publisher Site
http://dx.doi.org/10.1200/JCO.2002.20.3.694DOI Listing
February 2002